Instead, treatment with isobutyrate and propionate significantly downregulated TNF-α/IFN-γ-induced IL-6 and ICAM-1 in these cells, suggesting that the gut microbiome-derived metabolites isobutyrate and propionate are involved in the attenuation of inflammation in AD. Here, ICAM1 is linked to Alzheimer disease.